Editorially updated July 20, 2026. Prepared by SoCal Interventional using the clinical sources listed below. The tests needed for an individual patient must be selected by a qualified clinician.
BPH treatment should not be selected from prostate size or symptoms alone. The purpose of diagnostic evaluation is to determine whether benign prostate enlargement is causing the urinary problem, whether the bladder has been affected, and whether another condition must be addressed.
Not every patient needs every test. The AUA BPH guideline supports using history, examination, symptom burden, and selected testing to guide treatment.
Medical and medication history
A clinician will ask when symptoms began, how often they occur, how they affect sleep and daily activity, and whether retention, infection, bleeding, stones, or prior urinary procedures have occurred. Neurologic disease, diabetes, heart or kidney disease, sleep problems, sexual symptoms, and fluid habits may be relevant.
Prescription and over-the-counter medicines matter. Decongestants, antihistamines, diuretics, opioids, and other drugs can worsen or change urinary symptoms. A medication should not be stopped without appropriate medical guidance.
Symptom scores and patient goals
The International Prostate Symptom Score is commonly used to describe symptom severity and quality-of-life impact. It does not diagnose BPH by itself, but it creates a baseline that can be compared after treatment.
Patients should also define what improvement matters most: fewer nighttime trips, stronger flow, avoiding retention, reducing medication, minimizing anesthesia, preserving ejaculation, or obtaining the most powerful outlet relief. Different treatments prioritize these goals differently.
Urinalysis and laboratory testing
Urinalysis can identify findings that suggest infection, blood, glucose, or other problems. Kidney-function testing may be appropriate when retention, kidney disease, contrast use, or a procedure is being considered.
Prostate-specific antigen testing may be discussed based on age, life expectancy, risk, prior results, examination, and shared decision-making. PSA is not a BPH-only test and can be affected by multiple factors. Abnormal or changing results may require urologic evaluation before treatment.
Postvoid residual and urinary flow
Postvoid residual measures the urine left in the bladder after urination. A high value may reflect obstruction, weak bladder contraction, or both. Uroflowmetry measures the pattern and speed of urinary flow. These tests help characterize the problem but must be interpreted in context.
Bladder function matters because opening the prostate outlet may not completely resolve symptoms caused primarily by a weak or overactive bladder.
Prostate imaging
Ultrasound or MRI can estimate prostate volume and show anatomical features such as median-lobe enlargement. Imaging may also assess the bladder or urinary tract. Before prostate artery embolization, imaging can help evaluate prostate anatomy and procedural planning.
Arterial anatomy is assessed separately. Kidney function, contrast allergy, atherosclerosis, and connections between prostate arteries and nearby organs can affect PAE feasibility and risk.
Cystoscopy and urodynamic testing
Cystoscopy allows a urologist to inspect the urethra, prostate channel, and bladder. It may be useful when urethral narrowing, bladder disease, prior surgery, bleeding, or certain anatomical questions are present.
Urodynamic studies measure bladder pressure and function. They may help when symptoms, flow, and residual results do not clearly distinguish outlet obstruction from bladder dysfunction, or when neurologic disease or prior treatment complicates the picture.
How the findings guide treatment
Mild symptoms without complications may be monitored. Medication may be suitable for many patients. Procedure selection depends on anatomy, obstruction, retention, bleeding risk, sexual priorities, anesthesia tolerance, desired magnitude and speed of improvement, and willingness to accept retreatment.
PAE may be evaluated for selected patients with symptoms attributed to BPH and suitable clinical and arterial findings. TURP, HoLEP, aquablation, water-vapor therapy, prostatic urethral lift, and other options have different criteria and tradeoffs. Read the BPH treatment comparison and PAE versus TURP.
Sources
To request an evaluation in Irvine or Van Nuys, call (310) 929-0026. Bring prior urology records, imaging, laboratory results, and a current medication list when available.
Would a consultation help clarify your options?
Bring your symptoms, prior treatment, imaging, and goals. We will discuss whether an image-guided procedure—or another path—fits your situation.
Request an appointment